Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis

https://doi.org/10.1007/s10156-004-0332-4Get rights and content

Abstract

Twenty-three clinical strains of Chlamydia trachomatis were isolated from men with chlamydial nongonococcal urethritis and examined for the presence of fluoroquinolone resistance-associated alterations in GyrA and ParC. The minimum inhibitory concentrations (MICs) of fluoroquinolones, erythromycin, and tetracycline were determined for 6 of the 23 isolates. In 12 of the 23 isolates, a single amino-acid change was found in GyrA, and in 1 isolate, two amino acids were changed. In all 23 isolates, an Arg-83-to-Gly substitution was observed in ParC, and in 3 isolates, an additional amino-acid change was found. Some changes occurred within the quinolone resistance-determining regions (QRDRs) of GyrA and ParC, but not at positions critical for fluoroquinolone resistance. Of the 6 isolates for which MICs of the agents were determined, 1 isolate had a Cys-66 → Arg substitution in GyrA, and all had the Arg-83 → Gly substitution in ParC. However, all 6 isolates were susceptible to fluoroquinolones. First-pass urine specimens were obtained from two men who were positive for C. trachomatis after levofloxacin treatment, and the gyrA and parC genes of C. trachomatis were amplified by polymerase chain reaction (PCR) and examined for fluoroquinolone resistance-associated mutations. Pre- and post-treatment C. trachomatis persisting in each of them had identical amino-acid sequences in the QRDR of GyrA and ParC. Further, the substitutions found in GyrA and ParC were not located at positions critical for fluoroquinolone resistance. The present study suggests that fluoroquinolone resistance-associated alterations in GyrA and ParC may be uncommon in clinical strains of C. trachomatis.

References (26)

  • S. Nakamura

    Mechanisms of quinolone resistance

    J Infect Chemother

    (1997)
  • M. Yasuda et al.

    In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV

    J Urol

    (2000)
  • Centers for Disease Control and Prevention Guidelines for treatment of sexually transmitted diseases 2002

    Morb Mortal Wkly Rep

    (2002)
  • M.L. Joly-Guillou et al.

    Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis epididymitis and prostatitis

    Drugs

    (1999)
  • Japanese Society for Sexually Transmitted Diseases

    Guidelines for the diagnosis and treatment of sexually transmitted diseases. Jpn J Sex Transm Dis

    (1999)
  • J.C. Lefevre et al.

    Tetracycline-resistant Chlamydia trachomatis in Toulouse France

    Pathol Biol (Paris)

    (1997)
  • J. Somani et al.

    Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure

    J Infect Dis

    (2000)
  • S. Dessus-Babus et al.

    Sequencing of gyrase and topoisomerase IV quinoloneresistance- determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro

    Antimicrob Agents Chemother

    (1998)
  • I. Morrissey et al.

    Serial passage of Chlamydia spp In sub-inhibitory fluoroquinolone concentrations

    J Antimicrob Chemother

    (2002)
  • H. Yoshida et al.

    Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli

    Antimicrob Agents Chemother

    (1990)
  • N. Katoh et al.

    Isolation of Chlamydia trachomatis from patients with urethritis

    Kansenshogaku Zasshi

    (1984)
  • Japanese Society of Chemotherapy. Method for in vitro determination of chlamydial susceptibility (minimum inhibitory...
  • T. Yoshida et al.

    Phylogeny-based rapid identification of mycoplasmas and ureaplasmas from urethritis patients

    J Clin Microbiol

    (2002)
  • Cited by (18)

    • Macrolide and fluoroquinolone resistance is uncommon in clinical strains of Chlamydia trachomatis

      2018, Journal of Infection and Chemotherapy
      Citation Excerpt :

      However, we did find V61A and H129Q in GyrA in 44 specimens. In our previous study [19], we reported some amino acid changes, including V61A, in GyrA in 7 clinical isolates of C. trachomatis from male NGU, but we did not find any amino acid changes within the QRDRs of the gyrA gene in 23 clinical isolates. In two previous studies [20,21], the reference strains of C. trachomatis L2, which is a pathogen of lymphogranuloma venereum, were exposed to fluoroquinolones serially in vitro.

    View all citing articles on Scopus
    View full text